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Glycemic variability (GV) is reportedly a predictor for poor outcome in various clinical condi-
tions. We aimed to assess whether GV during hospital admission is associated with poor
outcomes in patients with acute ischemic stroke (AIS) and diabetes. We prospectively
enrolled consecutive patients with AIS from the registry of 6 tertiary hospitals between Janu-
ary 2013 and December 2014. For the GV index, we used a glucose level range that was
divided into 4 quartiles. Multivariable binary and ordinal logistic regression analyses were
performed to determine the association between GV and the modified Rankin Scale score
(3–6) at 3 months. We enrolled 1,504 patients with AIS and diabetes (mean age, 68.1 years;
male, 57.2%), of which 35.1% had poor outcomes at 3 months. An increasing glucose range
quartile was positively associated with initial neurologic severity and development of hypo-
glycemia during hospital admission. Multivariable analysis showed that the glucose level
range quartile was associated with poor outcomes, even after adjusting for the number of
glucose measurement and hypoglycemia (odds ratio [OR] Q2 vs. Q1: 1.50, 95% confidence
interval [CI]: 1.02–2.18; OR Q3 vs. Q1: 2.01, 95% CI: 1.34–3.01; OR Q4 vs. Q1: 1.98, 95%
CI: 1.22–3.23). These associations remained significant after dichotomization according to
glycated hemoglobin levels at admission. An increasing glucose level range as a GV index
during hospital admission was associated with poor functional outcomes at 3 months in
patients with AIS and diabetes.
Introduction
Diabetes is associated with increased risks and worse prognosis in cases with acute ischemic
stroke (AIS) [1,2]. Patients with hyperglycemia at admission and during hospitalization, which
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is primarily noted among diabetic patients, are more likely to have worse clinical outcomes as
compared to those with normoglycemia [3–5]. Hyperglycemia has a deleterious effect in cases
of cerebral ischemia due to increased oxidative stress [6], inflammation [7], apoptosis [8], and
inhibition of fibrinolysis [9]. However, the beneficial effects of intensive glucose lowering on
the clinical outcomes after AIS remain unclear.
In the Diabetes Control and Complications Trial, a reduction in the glycated hemoglobin
(A1c) levels was associated with a decreased incidence and progression of microvascular com-
plications in patients with diabetes [10]. However, the observation of a higher risk of retinopa-
thy progression in the conventional treatment group than in the intensive treatment group
with similar A1c levels suggests that glycemic variability (GV) could potentially be linked to
the development of diabetic complications [11]. Increased fluctuation of blood glucose levels is
reported to be associated with poor outcomes in critically ill patients [12,13]. Although several
studies have suggested that the nervous system is vulnerable to glycemic excursion [14,15], the
role of GV in the outcomes of patients with AIS remains unclear. Therefore, we hypothesized
that high GV would be associated with poor functional outcomes in patients with AIS, irre-
spective of the presence of hyper- or hypoglycemia. In the present study, we aimed to evaluate
the association between GV and functional prognosis in patients with diabetes after AIS.
Materials and methods
Study design and participants
We enrolled patients with AIS from 6 tertiary teaching hospitals who were admitted within 7
days of symptom onset, from January 2013 to December 2014. Of 4,376 patients with AIS, we
excluded 2,729 who were not diagnosed with diabetes, as glucose measurements during admis-
sion alone were not sufficient to indicate glycemic excursion in the usual clinical settings.
Moreover, we excluded patients who underwent glucose measurement less than 5 times during
admission (n = 132) and those with missing laboratory data (n = 11) (Fig 1). Written Informed
consent was obtained from all the patients or the authorized next of kin, and the institutional
review board (IRB) and ethics committee of each participating hospital (IRBs in Hanyang Uni-
versity Hospital, Chuncheon Sacred Heart Hospital, Seoul National University Hospital, Seoul
National University Seoul Metropolitan Government Boramae Medical Center, Kyung Hee
University Hospital and Seoul National University Bundang Hospital) approved this study.
Data collection
All the participating centers contributed to the prospective registry of the Clinical Research
Center for Stroke; the detailed methods of data collection have been described previously [16].
In brief, this registry includes information on patient demographics and clinical variables and
outcomes, in-hospital treatment including thrombolysis, and premorbid conditions including
risk factors. Stroke was classified as transient ischemic attack (TIA), large artery atherosclerosis
(LAA), small vessel occlusion (SVO), cardioembolic (CE) stroke, stroke of undetermined etiol-
ogy (SUE), or stroke of other determined etiology (SOE) according to Trial of ORG 10172 in
Acute Stroke Trial [17]. The stroke severity at admission was evaluated using the National
Institute Health Stroke Scale (NIHSS) score [18]. Hypertension was diagnosed in patients who
were taking antihypertensive medications or in patients with an average sitting blood pressure
of140 mmHg (systolic) or90 mmHg (diastolic). Diabetes was diagnosed in patients who
were receiving medical treatment for diabetes, in those with a fasting serum glucose level
of 126 mg/dL, or those with a non-fasting serum glucose level of 200 mg/dL, with corre-
sponding symptoms of diabetes, and in those with an admission A1c6.5%. Hyperlipidemia
was diagnosed in patients with a total cholesterol level of 240 mg/dL, or in patients who
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were treated with lipid lowering agents. Current smoking status was considered in patients
who smoked 1 or more cigarettes per day within the last 6 months.
Blood glucose measurement
All the admitted patients underwent immediate blood glucose measurement to rule out focal
neurologic deficits. After the initial assessment, the blood sugar levels were determined 4 times
daily (fasting state [7 AM], post-prandial [9 AM], before dinner [4 PM], and at night [10 PM])
by the finger prick method. Cases of hyperglycemia were managed according to the established
guidelines, which state that the blood glucose level should be maintained within 140–180 mg/
dL. If insulin was injected to maintain the optimal blood glucose level, additional blood tests
were permitted to determine whether sufficient blood glucose lowering was achieved or
whether the insulin injection induced hypoglycemia. However, blood sugar tests were not per-
formed for all patients after the acute period until an appropriate blood glucose level was
achieved. After the acute period of stroke, a blood glucose test was performed if the patients
exhibited a detrimental neurologic status or symptomatic hypo- and hyperglycemia. In other
Fig 1. Study participants.
https://doi.org/10.1371/journal.pone.0183894.g001
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cases, the glucose levels were managed as per the current guideline to prevent the development
of long-term complications of diabetes [19].
Glycemic variability index
Capillary glucose levels were obtained sequentially from admission to discharge by using an
electronic medical recording system. The mean and median values of glucose during admis-
sion were calculated. Hypoglycemia was defined as capillary blood glucose<70 mg/dL. There
is no gold standard measurement of glycemic excursion in clinical practice. Most of research-
ers agree that these standard GV measurement should be more sensitive, reliable, reproduc-
ible, and easy to understand [20]. Range of glucose is the one of the simplest and easiest
metrics to calculate, and this GV index is associated with the mortality in patients with acute
myocardial infarction [21] and with critically illnesses [22]. Therefore, the GV during hospital
admission was assessed as range (maximum–minimum) of glucose during the hospital admis-
sion. We excluded glucose values less than 10 or more than 600 mg/dL as an outlier.
Outcome
The functional outcome was assessed by using the modified Rankin Scale (mRS) score [23],
which was measured by experienced stroke neurologists or trained nurses during a visit to the
outpatient clinic or via a telephone interview. Accordingly, the mRS consists of 7 grades of
increasing disability, from 0 (no symptoms) to 6 (death). Poor functional outcome was defined
as a dichotomized mRS score of 3–6 at 3 months after stroke onset.
Statistical analysis
The bivariate correlations among glucose parameters, hypoglycemic episodes, and crude mRS
scores were examined using a Spearman’s rank correlation test. Baseline contingency table was
generated to determine the differences in the demographic and clinical characteristics based
on range of glucose 4 quartiles. Continuous variables are expressed as mean ± SD or median
(interquartile range, IQR), whereas categorical variables are expressed as number (%). The dif-
ferences in the baseline characteristics according to the blood glucose range quartiles were
examined using analysis of variance, with the Bonferroni post-hoc test and the Kruskal-Wallis
test for continuous variables, and with the Pearson’s chi-square test for categorical variables.
Univariable analyses of the predictors of poor functional outcome (dichotomized mRS 3–6) at
3 months after stroke onset were used to determine the unadjusted associations between the
dependent variables, including age, gender, stroke risk factors (prior history of stroke, hyper-
tension, hyperlipidemia, and current smoking), clinical characteristics (stroke subtype, stroke
severity, IV thrombolysis), and glucose parameters (number of glucose measurement, A1c
level, hypoglycemic event, and range of glucose quartile). The NIHSS score was an interval var-
iable with a non-normal distribution, and was hence divided into 4 groups: 0–1, 2–3, 4–6, and
7. We used the glucose range quartile as the dependent variable to estimate the odds ratios
(ORs) for poor functional outcome at 3 months after stroke onset. Multivariable binary logistic
regression analyses were performed using a tiered approach. First, the demographic variables
(age and sex) were added into the model. Second, the risk factors and characteristics of stroke
(thrombolysis, stroke severity, and subtype) were added to the model. The number of glucose
measurement and hypoglycemic event were included in the final model. In addition, mRS
score 5 and 6 were combined with one variable in multivariable ordinal logistic regression
analysis. Covariates with a variance inflation factor of>3 were removed from the model to
minimize the multicollinearity. Statistical significance was set at P<0.05, and all statistical
analyses were performed with the IBM SPSS 21.0 software.
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Results
Baseline characteristics
Among the 1,504 diabetic patients with AIS, the mean and median age was 68.1±10.7 and 70.0
(interquartile range, 61.0–76.0) years, respectively. And, the proportion of male patients was
57.2% (Table 1). Over a median period of 7.1 (range, 4.7–12.0) days of admission, a total of
57,584 capillary glucose measurements were sequentially conducted 28 (range, 18–46) times in
each patient. The measured capillary glucose values ranged from 15 to 587 mg/dL, and the
mean glucose value was 169±35 mg/dL. The mean A1c value was 7.4±1.7%. Hypoglycemia was
noted in 222 of 1,504 subjects (14.8%). LAA was the predominant stroke subtype in the study
population. Compared to patients with a lower glucose range quartile, those with a higher
Table 1. Baseline characteristics.
Range of glucose P value
Total
(N = 1,504)
Quartile 1 (0–129 mg/
dL, N = 383)
Quartile 2 (130–175 mg/
dL, N = 378)
Quartile 3 (176–235 mg/
dL, N = 371)
Quartile 4 (>235 mg/
dL, N = 372)
Age, years 68.1±10.7 68.6±11.1 67.8±10.4 68.3±10.8 67.8±10.6 0.375
Male, % 860 (57.2) 205 (53.5) 232 (61.4) 220 (59.3) 203 (54.6) 0.089
Risk factors, %
Previous stroke 393 (26.1) 91 (23.8) 96 (25.4) 95 (25.6) 111 (29.8) 0.270
Hypertension 1,114 (78.1) 315 (82.2) 301 (79.6) 277 (74.7) 281 (75.5) 0.039
Hyperlipidemia 648 (43.1) 187 (48.8) 171 (45.2) 159 (42.9) 131 (35.2) 0.002
Current smoking 376 (25.0) 92 (24.0) 90 (23.8) 107 (28.8) 87 (23.4) 0.271




TIA 56 (3.7) 21 (5.5) 13 (3.4) 13 (3.5) 9 (2.4)
LAA 534 (35.5) 133 (34.7) 119 (31.5) 143 (38.5) 139 (37.4)
SVO 428 (28.5) 101 (26.4) 124 (32.8) 110 (29.6) 93 (25.0)
CE 269 (17.9) 66 (17.2) 71 (18.8) 63 (17.0) 69 (18.5)
SOE 24 (1.6) 5 (1.3) 7 (1.9) 5 (1.3) 7 (1.9)
SUE 193 (12.8) 57 (14.9) 44 (11.6) 37 (10.0) 55 (14.8)
NIHSS score 3 (1, 6) 2 (1, 4) 3 (1, 6) 3 (1, 6) 4 (2, 8) <0.001




28 (18–46) 19 (13–25) 27 (18–38) 31 (22–50) 45 (30–73) <0.001
Mean, mg/dL 169±35 142±23 162±26 175±28 199±35 <0.001
Median, mg/dL 163±37 137±24 156±29 169±30 191±39 <0.001
Maximum, mg/dL 283±80 199±31 251±25 297±30 388±61 <0.001
Minimum, mg/dL 95±25 102±20 100±21 95±26 84±29 <0.001
at admission, mg/dL 182±76 145±40 167±55 183±63 235±103 <0.001
A1c, % 7.4±1.7 6.7±1.1 7.2±1.4 7.6±1.6 8.2±2.1 <0.001
Hypoglycemic event,
%
14.8 3.1 5.8 17 33.6 <0.001
Length of hospital
stay, days
7.2 (4.7–12.1) 5.3 (3.5–7.8) 6.8 (4.5–10.3) 7.2 (4.9–12.6) 10.6 (6.9–17.8) <0.001
TIA, transient ischemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment; LAA, Large Artery Atherosclerosis; SVO, Small Vessel Occlusion;
CE, Cardioembolism; SOE, Stroke of Other determined Etiology; SUE, Stroke of Undetermined Etiology; NIHSS, National Institutes of Health Stroke Scale;
IV, Intravenous; A1c, glycated hemoglobin.
https://doi.org/10.1371/journal.pone.0183894.t001
Glycemic variability and outcome after acute ischemic stroke
PLOS ONE | https://doi.org/10.1371/journal.pone.0183894 September 7, 2017 5 / 13
quartile more frequently had a history of hypertension and hyperlipidemia. The stroke severity
proportionally increased with an increase in the glucose range quartile (P<0.001, Kruskal-
Wallis test). In addition, 96 patients (6.4%) received thrombolysis, and the proportion of
patients who received thrombolysis did not differ according to the glucose range quartile. The
levels of glucose and A1c at admission, as well as the mean, median and maximum values of
the glucose parameters during admission proportionally increased in cases from the lowest to
highest glucose range quartile. In particular, the minimum value of the glucose parameters
decreased and the proportion of cases with hypoglycemia increased as the glucose range quar-
tile increased. Furthermore, the glucose range significantly differed (P<0.001, Kruskal-Wallis
test) according to the anti-diabetic treatment modality, with the lowest values in the no treat-
ment group and the highest values in the insulin group (S1 Fig).
Glucose parameters, crude mRS, and hypoglycemic event
All the participants had a median mRS score of 2 (range, 1–3) at 3 months after stroke onset. The
glucose value at admission was not correlated with a crude mRS score or hypoglycemic event in
our population (Table 2). Range of glucose was correlated to a significantly greater extent with the
crude mRS score (r = 0.201, P<0.001) and hypoglycemic event (r = 0.337, P<0.001).
Predictors of poor outcome
A total of 528 subjects (35.1%) had a poor functional outcome at 3 months after stroke onset.
In the univariable analysis, the mean glucose level (OR, 1.01; 95% confidence interval [CI],
1.01–1.01; P = 0.001) and hypoglycemic event (OR, 2.26; 95% CI: 1.70–3.02; P< 0.001) were
associated with poor outcomes (Table 3). However, the A1c level was not associated with poor
outcomes. Each glucose range quartile, relative to the first quartile, was positively associated
with increasing ORs for poor outcome at 3 months after stroke onset, according to the univari-
able analysis (P for chi-square trend<0.001).
In the multivariable binary logistic regression analysis (Table 4), the glucose range quartile
remained significant, after adjusting for age, gender, NIHSS quartile, IV thrombolysis, stroke
subtype, number of glucose measurement, and hypoglycemic event (OR for quartile 2 vs. 1:
1.50, 95% CI: 1.02–2.18; OR for quartile 3 vs. 1: 2.01, 95% CI: 1.34–3.01; OR for quartile 4 vs. 1:
1.98, 95% CI: 1.22–3.23). In addition, range of glucose quartile were positively associated with
Table 2. Matrix of correlation coefficient among crude modified Rankin Scale score, hypoglycemia rate and glucose parameters.
Characteristics (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
(1) Number of glucose measurements –
(2) Glucose at admission 0.098a –
(3) Mean 0.167a 0.510a –
(4) Median 0.154a 0.481a 0.968a –
(5) Maximum 0.421a 0.474a 0.787a 0.704a –
(6) Minimum 0.351a 0.172a 0.375a 0.364a 0.006 –
(7) Range 0.520a 0.389a 0.624a 0.551a 0.944a 0.238a –
(8) A1c 0.059a 0.375a 0.460a 0.439a 0.399a 0.148a 0.331a –
(8) mRS 0.375a -0.011 0.103a 0.100a 0.177a 0.124a 0.201a 0.046 –
(9) Hypoglycemia, % 0.283a 0.026 0.066a 0.069a 0.170a 0.614a 0.337a 0.034 0.138a –
A1c, glycated hemoglobin; mRS, modified Rankin Scale score
Values are presented with Spearman’s correlation coefficient.
aP value <0.05
https://doi.org/10.1371/journal.pone.0183894.t002
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increased risk of unfavorable shift in mRS score distribution (adjusted common OR for quar-
tile 2 vs. 1: 1.31, 95% CI: 0.99–1.74; OR for quartile 3 vs. 1: 1.72, 95% CI: 1.30–2.28; OR for
quartile 4 vs. 1: 2.46, 95% CI: 1.82–3.33; S1 Table).
We performed subgroup analysis wherein the glucose range was divided as high and low
based on the A1c values to compare the effect of the previous diabetic control status on the
functional outcome. Patients with a lower glucose range had a better outcome irrespective of
the A1c level at admission, as compared to those with a higher glucose range (Fig 2).
Relationships between length of hospital stay, frequency of hypoglycemic event and glucose
parameters are summarized in Fig 3. Length of hospital stay (Fig 3A) and frequency of hypo-
glycemic event (Fig 3B) was gradually increased as the quartiles of glucose range moved
toward the highest quartile. However, length of hospital stay was not significantly different
according to mean glucose level. Increased quartiles of mean glucose level was significantly
associated with a higher rate of hypoglycemic event.
Table 3. Univariable analyses of the predictors of poor functional outcome at 3 months after stroke onset.
Favorable outcome (N = 976) Poor outcome (N = 528) Univariable OR (95% CI) P value
Age, years 66.5±10.6 71.1±10.4 1.04 (1.03–1.06) <0.001
Gender, male (%) 60.5 51.1 0.67 (0.55–0.85) 0.001
Risk factor, %
Previous stroke 20.2 37.1 2.33 (1.84–2.96) <0.001
Hypertension 76.9 80.1 1.21 (0.93–1.57) 0.157
Hyperlipidemia 42.6 43.9 1.06 (0.85–1.31) 0.623
Current smoking 28.2 19.1 0.60 (0.47–0.78) <0.001
TIA and TOAST subtype, % 0.008
TIA 4.7 1.9 0.49 (0.24–1.00) 0.049
LAA 34.5 37.3 1.31 (1.00–1.72) 0.050
SVO 30.3 25.0 1.0 (reference) -
CE 16.7 20.1 1.46 (1.06–2.01) 0.021
SOE 1.7 1.3 0.92 (0.37–2.28) 0.863
SUE 12.0 14.4 1.46 (1.02–2.08) 0.037
NIHSS score, %
0–1 37.0 11.0 1.0 (reference) -
2–3 30.4 20.1 2.22 (1.56–3.17) <0.001
4–6 22.3 25.2 3.80 (2.67–5.40) <0.001
7 10.2 43.8 14.38 (10.00–20.67) <0.001
IV thrombolysis, % 4.8 9.3 2.02 (1.34–3.06) 0.001
Glucose parameters
Mean, mg/dL 167±34 173±36 1.01 (1.00–1.01) 0.001
Hypoglycemia rate, % 11.0 21.8 2.26 (1.70–3.02) <0.001
A1c, % 7.4±1.7 7.4±1.7 1.00 (0.94–1.07) 0.947
Range quartile, %
Q1 37.0 11.0 1.0 (reference) -
Q2 30.4 20.1 1.66 (1.20–2.29) 0.002
Q3 22.3 20.1 2.44 (1.78–3.36) <0.001
Q4 10.2 43.8 3.09 (2.26–4.25) <0.001
TIA, transient ischemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment; LAA, Large Artery Atherosclerosis; SVO, Small Vessel Occlusion;
CE, Cardioembolism; SOE, Stroke of Other determined Etiology; SUE, Stroke of Undetermined Etiology; NIHSS, National Institutes of Health Stroke Scale;
IV, Intravenous; A1c, glycated hemoglobin; Q1-4, quartile 1–4; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0183894.t003
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Discussion
In this retrospective observational study, we found that a high GV—represented by glucose
range quartiles—was associated with poor functional outcome at 3 months after stroke onset
in patients with diabetes and AIS. This association remained significant after adjusting for
number of glucose measurement and the hypoglycemic event. Range of glucose may be useful
to evaluate the association between glycemic excursion and functional outcome in patients
with AIS in actual clinical settings.
The association between GV and poor outcome in patients with AIS can be explained from
various viewpoints. First, an increased GV would indicate poor control of diabetes. In Table 1,
higher glucose range quartiles, relative to a low quartile, were associated with increased glucose
and A1c values at admission. Therefore, GV could serve as a marker for poor control of di-
abetes prior to stroke [24,25]. Second, hyperglycemia at admission has been reported to occur
as a result of stress response after stroke, wherein hyperglycemia is associated with an in-
creased cortisol level [26]. As the severity and lesion size of ischemic stroke increase, the serum
cortisol level would also proportionally increase [27–29], which could consequently result in
elevated glucose levels at admission. We found that the initial stroke severity was significantly
associated with an increased GV. This could be partially explained by the fact that high GV
reflects the severity of ischemic stroke. Third, several studies have shown that increased GV
Table 4. Multivariable binary logistic regression analyses of the predictors of poor functional outcomes at 3 months after stroke onset, according
to the range quartile.
Odds ratio (95% CI)
Range Q1 Range Q2 Range Q3 Range Q4
Crude Reference 1.66 (1.20–2.29) 2.44 (1.78–3.36) 3.09 (2.26–4.25)
Age- and sex-adjusted Reference 1.79 (1.29–2.50) 2.63 (1.90–3.65) 3.43 (2.47–4.74)
Model 1 Reference 1.79 (1.28–2.51) 2.67 (1.91–3.72) 3.41 (2.45–4.75)
Model 2 Reference 1.58 (1.10–2.27) 2.34 (1.64–3.35) 2.69 (1.88–3.86)
Model 3 Reference 1.60 (1.11–2.31) 2.36 (1.65–3.38) 2.69 (1.88–3.87)
Model 4 Reference 1.44 (1.00–2.08) 1.93 (1.33–2.79) 1.87 (1.26–2.78)
Model 5 Reference 1.44 (1.00–2.08) 1.86 (1.28–2.70) 1.72 (1.15–2.59)
CI, confidence interval; Q1–4, quartile 1–4.; CI, confidence interval.
Model 1: adjusted for history of stroke, hypertension, hyperlipidemia, and current smoking
Model 2: Model 1 plus adjustment for NIHSS score quartile and intravenous thrombolysis
Model 3: Model 2 plus adjustment for TOAST classification
Model 4: Model 3 plus adjustment for number of glucose measurements
Model 5: Model 4 plus adjustment for hypoglycemia.
https://doi.org/10.1371/journal.pone.0183894.t004
Fig 2. Distribution of the modified Rankin Scale (mRS) scores at 3 months after stroke onset according to the glucose range and glycated
hemoglobin (A1c) level.
https://doi.org/10.1371/journal.pone.0183894.g002
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could predict hypoglycemic episodes in patients with type 2 diabetes [29,30]. Hypoglycemia is
a significant predictor of worse outcomes in various clinical settings [31,32]. In our study, the
proportion of patients with hypoglycemia increased with an increase in the glucose quartile
range (Fig 3B). An increase in GV is known to be a marker for hypoglycemia [33,34]. Thus, an
increased glucose range could affect stroke outcomes via harmful impacts of overt or covert
hypoglycemia. In our data, length of hospital stay and frequency of hypoglycemic event was not
associated with an increased level of mean glucose level. Instead, increased frequency of hypogly-
cemic event were associated with an increased quartiles of range of glucose. Hypoglycemia may
be developed when physicians normalize the high level of glucose in acute clinical setting. We
could not be convinced whether hypoglycemia has a deleterious effect on stroke outcome. How-
ever, hypoglycemia should be prevented or reduced whenever possible because range of glucose
are positively associated with the development of hypoglycemia during hospital admission.
Intensive insulin therapy in patients with acute stroke failed to show of its efficacy in func-
tional outcome and mortality [35]. In our data, increased glycemic variability (range of glu-
cose) was associated with a higher usage of insulin treatment and a higher incidence of
hypoglycemia during admission (Fig 3B and S1 Fig). The effort to correct hyperglycemia as
well as to reduce glycemic variability could be lessen the effect of glucose normalization in
acute stroke trials because of the harmful effect of hypoglycemic event.
In our data, there were apparently higher proportion of patients with hypertension and dys-
lipidemia in lower glucose quartile range groups compared to those with higher glucose quar-
tile range group. Though we did not assess medication adherence of our participants, there is a
possibility for the high medication adherence in patients with higher glucose range quartile
than in those with lower quartile. In Table 1, patients with lower glucose range quartile showed
low admission glucose and A1c levels. These findings suggested that their medication adher-
ence might be higher than those with lower glucose range quartile, because medication adher-
ence was positively associated with the presence of multiple cardiovascular risk factors [36].
There were no “gold standard” for the assessment of glycemic excursion in patients with
diabetes and stroke [37]. It is unclear why the glucose range quartile during hospitalization is
Fig 3. Relationship between length of hospital stay (A), frequency of hypoglycemic event (B) and glucose parameters during admission.
https://doi.org/10.1371/journal.pone.0183894.g003
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associated to a greater extent with functional outcomes in AIS patients, as compared to the GV
indices, such as standard deviation (SD) or coefficient of variation (CV) of glucose values. All-
port et al studied the temporal profile of glucose levels in patients with AIS via continuous glu-
cose monitoring, and found that the glucose values fluctuated to a greater extent during the early
period after AIS than during the late period [38]. Hence, it is possible that the degree of GV
(including the SD or CV of the glucose values) could be minimized, as the measured glucose val-
ues included a greater number of values from the hyperacute period through the entire hospital
admission period. In another study, SD, CV, or mean absolute change of glucose levels during
the acute period were associated with mortality or poor prognosis in critically ill patients [39,40].
Accordingly, we suggested that the SD or CV of glucose values are more suitable for evaluating
GV in the hyperacute period, as compared to the glucose range. However, as frequent glucose
sampling during the hyperacute period was not recommended in our practice guidelines, it is
difficult to obtain the SD or CV of the glucose values only in the hyperacute period after stroke.
We collected all capillary glucose data during hospital admission. Several studies suggested
that glucose excursions in the acute period are more important than those in the chronic
period, when evaluating clinical outcomes [41,42]. However, post-stroke hyperglycemia could
develop more than 48 hours after symptom onset [38]. Hypoglycemia may develop during the
chronic period as iatrogenic hypoglycemia due to the persistent use of anti-diabetic treatment
or the relative paucity of glucose monitoring during this period. The glucose range reflects the
fluctuations in the entire glucose profile in a simple manner. Moreover, the glucose range is
easier to calculate and use to make clinical decisions, as compared to the SD or CV of the glu-
cose values. In fact, a reduction in the glucose range by 10 points is more intuitive as compared
to a reduction of 10% in the SD or CV of the glucose values. In this perspectives, reducing
range of glucose during hospital admission might be effective management strategy in reduc-
ing the development of hypoglycemia and in finally improving functional outcomes in patients
with an acute ischemic stroke.
Our study has several limitations. First, we could not show a causal relationship between
GV and functional outcome in patients with AIS due to the retrospective nature of our obser-
vations. Second, we could not consider the differential effect of nutritional status on GV and
outcomes. Although continuous glucose monitoring data showed that glycemic profiles did
not differ according to feeding status or diabetes status [39], the relationship between GV and
nutritional status should be investigated in future studies, as nutritional status is associated
with the development of hypoglycemia. Third, the exclusion of some patients (for example,
due to the unavailability of glucose measurement data) could weaken the generalizability of
our data in diabetic patients with AIS.
Conclusions
In conclusion, we found that the glucose range, as a GV index, is positively associated with
poor functional outcomes at 3 months after stroke onset in diabetic patients with AIS. This
harmful association remained significant irrespective of number of glucose measurement or
hypoglycemic event, and the glucose range remained a significant predictor of worse outcome.
Future prospective study should assess whether GV improvement after AIS can lead to
improved functional outcomes.
Supporting information
S1 Fig. Results of the Kruskal-Wallis test showing the glucose range against the types of
anti-diabetic treatment. OHA, oral hypoglycemic agent.
(TIF)
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S1 Table. Multivariable ordinal logistic regression analyses of the predictors of unfavor-
able shift in modified Rankin Scale score distribution at 3 month. OR, odds ratio; CI, confi-
dence interval; TIA, transient ischemic attack; TOAST, Trial of Org 10172 in Acute Stroke
Treatment; LAA, Large Artery Atherosclerosis; SVO, Small Vessel Occlusion; CE, Cardioem-
bolism; SOE, Stroke of Other determined Etiology; SUE, Stroke of Undetermined Etiology;
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